CD274 and neoplasm: Firstly, because PD-L1 immunohistochemistry staining is not a mandatory test for patients who will receive 2+-line therapy or in combination with platinum based first-line therapy, therefore no PD-L1 tumor proportion score (PD-L1 TPS) expression was recorded and reported in current study.